Genetic variants and the metabolic syndrome: A systematic review

Obesity Reviews

Volumn 12, Issue 11, 2011, Pages 952-967

  Povel, C M ^a,b   Boer, J M A ^a   Reiling, E ^a   Feskens, E J M ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Metabolic syndrome; SNPs; Systematic review

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 2;

ARTICLE; DATA ANALYSIS; DATA BASE; DATA EXTRACTION; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LIPID METABOLISM; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; METABOLIC SYNDROME X; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80054831058     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2011.00907.x     Document Type: Article

References (119)

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA etal. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
2. Bosy-Westphal A, Onur S, Geisler C, Wolf A, Korth O, Pfeufferm M etal. Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. Int J Obes (Lond) 2007; 31: 784-790.
3. Henneman P, Aulchenko YS, Frants RR, van Dijk KW, Oostra BA, van Duijn CM. Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch isolate: the Erasmus Rucphen Family study. J Med Genet 2008; 45: 572-577.
4. Bellia A, Giardina E, Lauro D, Tesauro M, Di Fede G, Cusumano G etal. 'The Linosa Study': epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. Nutr Metab Cardiovasc Dis 2009; 19: 455-461.
5. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ. A navigator for human genome epidemiology. Nat Genet 2008; 40: 124-125.
6. Palomaki GE, Melillo S, Bradley LA. Association between 9p21 genomic markers and heart disease: a meta-analysis. JAMA 2010; 303: 648-656.
7. Montagnana M, Fava C, Nilsson PM, Engstrom G, Hedblad B, Lippi G etal. The Pro12Ala polymorphism of the PPARG gene is not associated with the metabolic syndrome in an urban population of middle-aged Swedish individuals. Diabet Med 2008; 25: 902-908.
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
9. Frederiksen L, Brodbaek K, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S etal. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002; 87: 3989-3992.
10. Meirhaeghe A, Cottel D, Amouyel P, Dallongeville J. Lack of association between certain candidate gene polymorphisms and the metabolic syndrome. Mol Genet Metab 2005; 86: 293-299.
11. Vimaleswaran KS, Radha V, Deepa R, Mohan V. Absence of association of metabolic syndrome with PPARGC1A, PPARG and UCP1 gene polymorphisms in Asian Indians. Metab Syndr Relat Disord 2007; 5: 153-162.
12. Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH etal. Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome. Arch Med Res 2006; 37: 86-94.
13. Fiorito M, Torrente I, De Cosmo S, Guida V, Colosimo A, Prudente S etal. Interaction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome. Obesity (Silver Spring) 2007; 15: 2889-2895.
14. Dongxia L, Qi H, Lisong L, Jincheng G. Association of peroxisome proliferator-activated receptorgamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome. Circ J 2008; 72: 551-557.
15. Ranjith N, Pegoraro RJ, Naidoo DP, Shanmugam R, Rom L. Genetic variants associated with insulin resistance and metabolic syndrome in young Asian Indians with myocardial infarction. Metab Syndr Relat Disord 2008; 6: 209-214.
16. Milewicz A, Tworowska-Bardzinska U, Dunajska K, Jedrzejuk D, Lwow F. Relationship of PPARgamma2 polymorphism with obesity and metabolic syndrome in postmenopausal Polish women. Exp Clin Endocrinol Diabetes 2009; 117: 628-632.
17. Haseeb A, Iliyas M, Chakrabarti S, Farooqui AA, Naik SR, Ghosh S etal. Single-nucleotide polymorphisms in peroxisome proliferator-activated receptor gamma and their association with plasma levels of resistin and the metabolic syndrome in a South Indian population. J Biosci 2009; 34: 405-414.
18. Miller M, Rhyne J, Chen H, Beach V, Ericson R, Luthra K etal. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res 2007; 38: 444-451.
19. Tellechea ML, Aranguren F, Perez MS, Cerrone GE, Frechtel GD, Taverna MJ. Pro12Ala polymorphism of the peroxisome proliferatoractivated receptor-gamma gene is associated with metabolic syndrome and surrogate measures of insulin resistance in healthy men: interaction with smoking status. Circ J 2009; 73: 2118-2124.
20. McCarthy JJ, Meyer J, Moliterno DJ, Newby LK, Rogers WJ, Topol EJ. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum Genet 2003; 114: 87-98.
21. Yamada Y, Kato K, Hibino T, Yokoi K, Matsuo H, Segawa T etal. Prediction of genetic risk for metabolic syndrome. Atherosclerosis 2007; 191: 298-304.
22. Meirhaeghe A, Cottel D, Amouyel P, Dallongeville J. Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women. Diabetes 2005; 54: 3043-3048.
23. Sarzani R, Salvi F, Bordicchia M, Pietrucci F, Caraceni D, Lancioni L etal. TCF7L2 alleles and metabolic syndrome in non-diabetic obese hypertensive patients. J Hum Hypertens 2008; 22: 373-375.
24. Saadi H, Nagelkerke N, Carruthers SG, Benedict S, Abdulkhalek S, Reed R etal. Association of TCF7L2 polymorphism with diabetes mellitus, metabolic syndrome, and markers of beta cell function and insulin resistance in a population-based sample of Emirati subjects. Diabetes Res Clin Pract 2008; 80: 392-398.
25. Warodomwichit D, Arnett DK, Kabagambe EK, Tsai MY, Hixson JE, Straka RJ etal. Polyunsaturated fatty acids modulate the effect of TCF7L2 gene variants on postprandial lipemia. J Nutr 2009; 139: 439-446.
26. Marzi C, Huth C, Kolz M, Grallert H, Meisinger C, Wichmann HE etal. Variants of the transcription factor 7-like 2 gene (TCF7L2) are strongly associated with type 2 diabetes but not with the metabolic syndrome in the MONICA/KORA surveys. Horm Metab Res 2007; 39: 46-52.
27. Melzer D, Murray A, Hurst AJ, Weedon MN, Bandinelli S, Corsi AM etal. Effects of the diabetes linked TCF7L2 polymorphism in a representative older population. BMC Med 2006; 4: 34.
28. Mattei J, Demissie S, Tucker KL, Ordovas JM. Apolipoprotein A5 polymorphisms interact with total dietary fat intake in association with markers of metabolic syndrome in Puerto Rican older adults. J Nutr 2009; 139: 2301-2308.
29. Dallongeville J, Cottel D, Wagner A, Ducimetiere P, Ruidavets JB, Arveiler D etal. The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglycerides. BMC Med Genet 2008; 9: 84.
30. Maasz A, Kisfali P, Horvatovich K, Mohas M, Marko L, Csongei V etal. Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol Oncol Res 2007; 13: 243-247.
31. Grallert H, Sedlmeier EM, Huth C, Kolz M, Heid IM, Meisinger C etal. APOA5 variants and metabolic syndrome in Caucasians. J Lipid Res 2007; 48: 2614-2621.
32. Komurcu-Bayrak E, Onat A, Poda M, Humphries SE, Palmen J, Guclu F etal. Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults. Clin Chem Lab Med 2008; 46: 778-784.
33. Hsu LA, Ko YL, Chang CJ, Teng MS, Wu S, Hu CF. Apolipoprotein A5 gene -1131T/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan. Clin Chem Lab Med 2008; 46: 1714-1719.
34. Niculescu LS, Vladica M, Sima AV. Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome. Biochem Biophys Res Commun 2009; 391: 587-591.
35. Pollex RL, Hanley AJ, Zinman B, Harris SB, Khan HM, Hegele RA. Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. Atherosclerosis 2006; 184: 121-129.
36. Ranjith N, Pegoraro RJ, Rom L. Lipid profiles and associated gene polymorphisms in young Asian Indian patients with acute myocardial infarction and the metabolic syndrome. Metab Syndr Relat Disord 2009; 7: 571-578.
37. Sima A, Iordan A, Stancu C. Apolipoprotein E polymorphism - a risk factor for metabolic syndrome. Clin Chem Lab Med 2007; 45: 1149-1153.
38. Olivieri O, Martinelli N, Bassi A, Trabetti E, Girelli D, Pizzolo F etal. ApoE epsilon2/epsilon3/epsilon4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome. Clin Exp Med 2007; 7: 164-172.
39. Junyent M, Lee Y, Smith CE, Arnett DK, Tsai MY, Kabagambe EK etal. The effect of a novel intergenic polymorphism (rs11774572) on HDL-cholesterol concentrations depends on TaqIB polymorphism in the cholesterol ester transfer protein gene. Nutr Metab Cardiovasc Dis 2010; 20: 34-40.
40. Ozsait B, Komurcu Bayrak E, Poda M, Can G, Hergenc G, Onat A etal. CETP TaqIB polymorphism in Turkish adults: association with dyslipidemia and metabolic syndrome. Anadolu Kardiyol Derg 2008; 8: 324-330.
41. Sandhofer A, Tatarczyk T, Laimer M, Ritsch A, Kaser S, Paulweber B etal. The Taq1B-variant in the cholesteryl ester-transfer protein gene and the risk of metabolic syndrome. Obesity (Silver Spring) 2008; 16: 919-922.
42. Andersen G, Overgaard J, Albrechtsen A, Glumer C, Borch-Johnsen K, Jorgensen T etal. Studies of the association of the GNB3 825C>T polymorphism with components of the metabolic syndrome in white Danes. Diabetologia 2006; 49: 75-82.
43. Onat A, Komurcu-Bayrak E, Can G, Kucukdurmaz Z, Hergenc G, Erginel-Unaltuna N. Apolipoprotein A-I positively associated with diabetes in women independently of apolipoprotein E genotype and apolipoprotein B levels. Nutrition 2010; 26: 975-980.
44. Tonjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006; 29: 2489-2497.
45. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J etal. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287.
46. Sjogren M, Lyssenko V, Jonsson A, Berglund G, Nilsson P, Groop L etal. The search for putative unifying genetic factors for components of the metabolic syndrome. Diabetologia 2008; 51: 2242-2251.
47. Yang LL, Hua Q, Liu RK, Yang Z. Association between two common polymorphisms of PPARgamma gene and metabolic syndrome families in a Chinese population. Arch Med Res 2009; 40: 89-96.
48. Guettier JM, Georgopoulos A, Tsai MY, Radha V, Shanthirani S, Deepa R etal. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J Clin Endocrinol Metab 2005; 90: 1705-1711.
49. Smith U. TCF7L2 and type 2 diabetes - we WNT to know. Diabetologia 2007; 50: 5-7.
50. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J etal. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Gene 2006; 38: 320-323.
51. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
52. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
53. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA etal. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005; 280: 21553-21560.
54. Yamada Y, Ichihara S, Kato K, Yoshida T, Yokoi K, Matsuo H etal. Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people. J Med Genet 2008; 45: 22-28.
55. Kisfali P, Mohas M, Maasz A, Hadarits F, Marko L, Horvatovich K etal. Apolipoprotein A5 IVS3+476A allelic variant associates with increased trigliceride levels and confers risk for development of metabolic syndrome in Hungarians. Circ J 2008; 72: 40-43.
56. Kisfali P, Mohas M, Maasz A, Polgar N, Hadarits F, Marko L etal. Haplotype analysis of the apolipoprotein A5 gene in patients with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2010; 20: 505-511.
57. Waterworth DM, Ribalta J, Nicaud V, Dallongeville J, Humphries SE, Talmud P. ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation 1999; 99: 1872-1877.
58. Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol 1997; 17: 2753-2758.
59. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F etal. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 2003; 44: 2374-2381.
60. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992; 33: 447-454.
61. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP etal. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008; 299: 2777-2788.
62. Loos RJ, Bouchard C. FTO: the first gene contributing to common forms of human obesity. Obes Rev 2008; 9: 246-250.
63. Freathy RM, Timpson NJ, Lawlor DA, Pouta A, Ben-Shlomo Y, Ruokonen A etal. Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes 2008; 57: 1419-1426.
64. Al-Attar SA, Pollex RL, Ban MR, Young TK, Bjerregaard P, Anand SS etal. Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. Cardiovasc Diabetol 2008; 7: 5.
65. Attaoua R, Ait El Mkadem S, Radian S, Fica S, Hanzu F, Albu A etal. FTO gene associates to metabolic syndrome in women with polycystic ovary syndrome. Biochem Biophys Res Commun 2008; 373: 230-234.
66. Attaoua R, Ait El Mkadem S, Lautier C, Kaouache S, Renard E, Brun JF etal. Association of the FTO gene with obesity and the metabolic syndrome is independent of the IRS-2 gene in the female population of Southern France. Diabetes Metab 2009; 35: 476-483.
67. Shimaoka I, Kamide K, Ohishi M, Katsuya T, Akasaka H, Saitoh S etal. Association of gene polymorphism of the fat-mass and obesity-associated gene with insulin resistance in Japanese. Hypertens Res 2010; 33: 214-218.
68. Stephens JW, Hurel SJ, Lowe GD, Rumley A, Humphries SE. Association between plasma IL-6, the IL6 -174G>C gene variant and the metabolic syndrome in type 2 diabetes mellitus. Mol Genet Metab 2007; 90: 422-428.
69. Hamid YH, Rose CS, Urhammer SA, Glumer C, Nolsoe R, Kristiansen OP etal. Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia 2005; 48: 251-260.
70. Grallert H, Huth C, Kolz M, Meisinger C, Herder C, Strassburger K etal. IL-6 promoter polymorphisms and quantitative traits related to the metabolic syndrome in KORA S4. Exp Gerontol 2006; 41: 737-745.
71. Norata GD, Ongari M, Garlaschelli K, Tibolla G, Grigore L, Raselli S etal. Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. J Intern Med 2007; 262: 104-112.
72. Qasim AN, Metkus TS, Tadesse M, Lehrke M, Restine S, Wolfe ML etal. Resistin gene variation is associated with systemic inflammation but not plasma adipokine levels, metabolic syndrome or coronary atherosclerosis in nondiabetic Caucasians. Clin Endocrinol (Oxf) 2009; 70: 698-705.
73. Goyenechea E, Collins LJ, Parra D, Abete I, Crujeiras AB, O'Dell SD etal. The -11391 G/A polymorphism of the adiponectin gene promoter is associated with metabolic syndrome traits and the outcome of an energy-restricted diet in obese subjects. Horm Metab Res 2009; 41: 55-61.
74. Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S etal. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 2004; 43: 1195-1200.
75. Yang WS, Yang YC, Chen CL, Wu IL, Lu JY, Lu FH etal. Adiponectin SNP276 is associated with obesity, the metabolic syndrome, and diabetes in the elderly. Am J Clin Nutr 2007; 86: 509-513.
76. Francke S, Manraj M, Lacquemant C, Lecoeur C, Lepretre F, Passa P etal. A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum Mol Genet 2001; 10: 2751-2765.
77. Ronconi V, Turchi F, Rilli S, Di Mattia D, Agostinelli L, Boscaro M etal. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. Nutr Metab Cardiovasc Dis 2010; 20: 93-100.
78. Menzaghi C, Salvemini L, Paroni G, De Bonis C, Mangiacotti D, Fini G etal. Circulating high molecular weight adiponectin isoform is heritable and shares a common genetic background with insulin resistance in nondiabetic White Caucasians from Italy: evidence from a family-based study. J Intern Med 2010; 267: 287-294.
79. Wang ZL, Xia B, Shrestha U, Jiang L, Ma CW, Chen Q etal. Correlation between adiponectin polymorphisms and non-alcoholic fatty liver disease with or without metabolic syndrome in Chinese population. J Endocrinol Invest 2008; 31: 1086-1091.
80. Hwang JY, Park JE, Choi YJ, Huh KB, Kim WY. SNP276G>T polymorphism in the adiponectin gene is associated with metabolic syndrome in patients with Type II diabetes mellitus in Korea. Eur J Clin Nutr 2010; 64: 105-107.
81. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 2007; 56: 1198-1209.
82. Mesa JL, Loos RJ, Franks PW, Ong KK, Luan J, O'Rahilly S etal. Lamin A/C polymorphisms, type 2 diabetes, and the metabolic syndrome: case-control and quantitative trait studies. Diabetes 2007; 56: 884-889.
83. Steinle NI, Kazlauskaite R, Imumorin IG, Hsueh WC, Pollin TI, O'Connell JR etal. Variation in the lamin A/C gene: associations with metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 1708-1713.
84. Urbanek M, Nampiaparampil G, D'Souza J, Sefton E, Ackerman C, Legro RS etal. The role of genetic variation in the lamin a/c gene in the etiology of polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94: 2665-2669.
85. Fontaine-Bisson B, Alessi MC, Saut N, Fumeron F, Marre M, Dutour A etal. Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR prospective study. J Mol Med 2009; 88: 193-201.
86. Dallongeville J, Helbecque N, Cottel D, Amouyel P, Meirhaeghe A. The Gly16->Arg16 and Gln27->Glu27 polymorphisms of beta2-adrenergic receptor are associated with metabolic syndrome in men. J Clin Endocrinol Metab 2003; 88: 4862-4866.
87. Tamaki S, Nakamura Y, Tabara Y, Okamura T, Kita Y, Kadowaki T etal. Relationship between metabolic syndrome and Trp64arg polymorphism of the beta-adrenergic receptor gene in a general sample: the Shigaraki study. Hypertens Res 2006; 29: 891-896.
88. Frederiksen L, Brodbaek K, Fenger M, Madsbad S, Urhammer SA, Jorgensen T etal. No interactions between polymorphisms in the beta3-adrenergic receptor gene and the PPAR-gamma gene on the risk of the insulin resistance syndrome in the Danish MONICA cohort. Diabetologia 2003; 46: 729-731.
89. Dunajska K, Lwow F, Milewicz A, Jedrzejuk D, Laczmanski L, Belowska-Bien K etal. beta(3)-adrenergic receptor polymorphism and metabolic syndrome in postmenopausal women. Gynecol Endocrinol 2008; 24: 133-138.
90. Phillips CM, Goumidi L, Bertrais S, Field MR, Ordovas JM, Cupples LA etal. Leptin receptor polymorphisms interact with polyunsaturated fatty acids to augment risk of insulin resistance and metabolic syndrome in adults. J Nutr 2009; 140: 238-244.
91. Gottlieb MG, Bodanese LC, Leite LE, Schwanke CH, Piccoli Jda C, da Rocha MI etal. Association between the Gln223Arg polymorphism of the leptin receptor and metabolic syndrome in free-living community elderly. Metab Syndr Relat Disord 2009; 7: 341-348.
92. Paracchini V, Pedotti P, Taioli E. Genetics of leptin and obesity: a HuGE review. Am J Epidemiol 2005; 162: 101-114.
93. Robitaille J, Gaudet D, Perusse L, Vohl MC. Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians. Int J Obes (Lond) 2007; 31: 411-417.
94. Grarup N, Albrechtsen A, Ek J, Borch-Johnsen K, Jorgensen T, Schmitz O etal. Variation in the peroxisome proliferator-activated receptor delta gene in relation to common metabolic traits in 7495 middle-aged white people. Diabetologia 2007; 50: 1201-1208.
95. Ambye L, Rasmussen S, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S etal. Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) gene in Danish subjects with the metabolic syndrome. Diabetes Res Clin Pract 2005; 67: 175-179.
96. Albala C, Villarroel A, Santos JL, Angel B, Lera L, Liberman C etal. FABP2 Ala54Thr polymorphism and diabetes in Chilean elders. Diabetes Res Clin Pract 2007; 77: 245-250.
97. Vimaleswaran KS, Radha V, Mohan V. Thr54 allele carriers of the Ala54Thr variant of FABP2 gene have associations with metabolic syndrome and hypertriglyceridemia in urban South Indians. Metabolism 2006; 55: 1222-1226.
98. Erkkila AT, Lindi V, Lehto S, Pyorala K, Laakso M, Uusitupa MI. Variation in the fatty acid binding protein 2 gene is not associated with markers of metabolic syndrome in patients with coronary heart disease. Nutr Metab Cardiovasc Dis 2002; 12: 53-59.
99. Labruna G, Pasanisi F, Nardelli C, Tarantino G, Vitale DF, Bracale R etal. UCP1 -3826 AG+GG genotypes, adiponectin, and leptin/adiponectin ratio in severe obesity. J Endocrinol Invest 2009; 32: 525-529.
100. Shen H, Qi L, Tai ES, Chew SK, Tan CE, Ordovas JM. Uncoupling protein 2 promoter polymorphism -866G/A, central adiposity, and metabolic syndrome in Asians. Obesity (Silver Spring) 2006; 14: 656-661.
101. Lee YH, Kim W, Yu BC, Park BL, Kim LH, Shin HD. Association of the ins/del polymorphisms of uncoupling protein 2 (UCP2) with BMI in a Korean population. Biochem Biophys Res Commun 2008; 371: 767-771.
102. Saez ME, Gonzalez-Sanchez JL, Ramirez-Lorca R, Martinez-Larrad MT, Zabena C, Gonzalez A etal. The CAPN10 gene is associated with insulin resistance phenotypes in the Spanish population. PLoS ONE 2008; 3: e2953.
103. Wiltgen D, Furtado L, Kohek MB, Spritzer PM. CAPN10 UCSNP-43, UCSNP-19 and UCSNP-63 polymorphisms and metabolic syndrome in polycystic ovary syndrome. Gynecol Endocrinol 2007; 23: 173-178.
104. Kang ES, Nam M, Kim HJ, Kim HJ, Myoung SM, Rhee Y etal. Haplotype combination of Calpain-10 gene polymorphism is associated with metabolic syndrome in type 2 diabetes. Diabetes Res Clin Pract 2006; 73: 268-275.
105. Saez ME, Martinez-Larrad MT, Ramirez-Lorca R, Gonzalez-Sanchez JL, Zabena C, Martinez-Calatrava MJ etal. Calpain-5 gene variants are associated with diastolic blood pressure and cholesterol levels. BMC Med Genet 2007; 8: 1.
106. Santoro N, Cirillo G, Lepore MG, Palma A, Amato A, Savarese P etal. Effect of the rs997509 polymorphism on the association between ectonucleotide pyrophosphatase phosphodiesterase 1 and metabolic syndrome and impaired glucose tolerance in childhood obesity. J Clin Endocrinol Metab 2009; 94: 300-305.
107. Gonzalez-Sanchez JL, Zabena C, Martinez-Larrad MT, Martinez-Calatrava MJ, Perez-Barba M, Serrano-Rios M. Association of ENPP1 (PC-1) K121Q polymorphism with obesity-related parameters in subjects with metabolic syndrome. Clin Endocrinol (Oxf) 2008; 68: 724-729.
108. Tasic I, Milojkovic M, Sunder-Plassmann R, Lazarevic G, Tasic NM, Stefanovic V. The association of PC-1 (ENPP1) K121Q polymorphism with metabolic syndrome in patients with coronary heart disease. Clin Chim Acta 2007; 377: 237-242.
109. Rose CS, Ek J, Urhammer SA, Glumer C, Borch-Johnsen K, Jorgensen T etal. A -30G>A polymorphism of the beta-cell-specific glucokinase promoter associates with hyperglycemia in the general population of whites. Diabetes 2005; 54: 3026-3031.
110. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM etal. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889-894.
111. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D etal. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445: 881-885.
112. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU etal. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42: 105-116.
113. Huth C, Illig T, Herder C, Gieger C, Grallert H, Vollmert C etal. Joint analysis of individual participants' data from 17 studies on the association of the IL6 variant -174G>C with circulating glucose levels, interleukin-6 levels, and body mass index. Ann Med 2009; 41: 128-138.
114. Sie MP, Sayed-Tabatabaei FA, Oei HH, Uitterlinden AG, Pols HA, Hofman A etal. Interleukin 6 -174g/c promoter polymorphism and risk of coronary heart disease: results from the rotterdam study and a meta-analysis. Arterioscler Thromb Vasc Biol 2006; 26: 212-217.
115. Waterworth DM, Talmud PJ, Humphries SE, Wicks PD, Sagnella GA, Strazzullo P etal. Variable effects of the APOC3-482C >T variant on insulin, glucose and triglyceride concentrations in different ethnic groups. Diabetologia 2001; 44: 245-248.
116. Festen EA, Goyette P, Green T, Boucher G, Beauchamp C, Trynka G etal. A Meta-Analysis of Genome-Wide Association Scans Identifies IL18RAP, PTPN2, TAGAP, and PUS10 As Shared Risk Loci for Crohn's Disease and Celiac Disease. Plos Genet 2011; 7: e1001283.
117. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
118. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
119. Hahne P, Krempler F, Schaap FG, Soyal SM, Hoffinger H, Miller K etal. Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans. J Intern Med 2008; 264: 452-462.